Early initiation: 1 trials - IMPROVE-IT
| ezetimibe vs placebo (on top statins) | cardiovascular events by 6% (fully demonstrated) suggested Coronary event by 13% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.94 [0.89 0.99] | p=0.04 | 0 | 18144 | 1 | IMPROVE-IT, | | Cardiovascular death | 1.00 [0.89 1.13] | p=1.00 | 0 | 18144 | 1 | IMPROVE-IT, | | stroke (fatal and non fatal) | 0.86 [0.73 1.01] | p=1.00 | 0 | 18144 | 1 | IMPROVE-IT, | | Coronary event | 0.87 [0.80 0.95] | p=0.04 | 0 | 18144 | 1 | IMPROVE-IT, | | Coronary death | 0.96 [0.84 1.09] | p=1.00 | 0 | 18144 | 1 | IMPROVE-IT, | | End stage renal disease | no data | | All cause death | 0.99 [0.91 1.07] | p=1.00 | 0 | 18144 | 1 | IMPROVE-IT, | | Fatal stroke | no data | | Cancer | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All chronical situations: 4 trials - IMPROVE-IT - SHARP - SANDS - ARBITER-HALTS 6
| aggressive treatment vs standard teatment | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Venous thromboembolism | no data | | cardiovascular events | 1.35 [0.53 3.41] | p=1.00 | 0 | 499 | 1 | SANDS, | | Cardiovascular death | no data | | stroke (fatal and non fatal) | no data | | Coronary event | no data | | Coronary death and non fatal MI | no data | | Coronary death | no data | | cardiac death | no data | | MACE | no data | | Non fatal MI | no data | | All cause death | no data | | non cardiovascular death | 0.49 [0.09 2.70] | p=1.00 | 0 | 499 | 1 | SANDS, | | Fatal stroke | no data | | Haemmorhagic stroke | no data | | new-onset diabetes | no data | | Death from cancer | no data | | Rhabdomyolysis | no data | | Myopathy | no data | | Cancer | no data | | Adverse events | 1.32 [0.88 1.98] | p=1.00 | 0 | 499 | 1 | SANDS, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| ezetimibe vs niacin | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | stroke (fatal and non fatal) | no data | | Coronary event | no data | | Coronary death | no data | | End stage renal disease | no data | | All cause death | no data | | Fatal stroke | no data | | Cancer | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| ezetimibe vs placebo (on top statins) | cardiovascular events by 6% (fully demonstrated) suggested Coronary event by 13% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.94 [0.89 0.99] | p=0.04 | 0 | 18144 | 1 | IMPROVE-IT, | | Cardiovascular death | 1.00 [0.89 1.13] | p=1.00 | 0 | 18144 | 1 | IMPROVE-IT, | | stroke (fatal and non fatal) | 0.86 [0.73 1.01] | p=1.00 | 0 | 18144 | 1 | IMPROVE-IT, | | Coronary event | 0.87 [0.80 0.95] | p=0.04 | 0 | 18144 | 1 | IMPROVE-IT, | | Coronary death | 0.96 [0.84 1.09] | p=1.00 | 0 | 18144 | 1 | IMPROVE-IT, | | End stage renal disease | no data | | All cause death | 0.99 [0.91 1.07] | p=1.00 | 0 | 18144 | 1 | IMPROVE-IT, | | Fatal stroke | no data | | Cancer | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| ezetimibe+simvastatin vs placebo | No demonstrated result suggested cardiovascular events by 13% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.87 [0.78 0.97] | p=0.04 | 0 | 9270 | 1 | SHARP, | | Cardiovascular death | no data | | stroke (fatal and non fatal) | no data | | Coronary event | 0.92 [0.76 1.11] | p=1.00 | 0 | 9270 | 1 | SHARP, | | Coronary death | no data | | End stage renal disease | 0.97 [0.88 1.07] | p=1.00 | 0 | 9270 | 1 | SHARP, | | All cause death | 1.02 [0.93 1.12] | p=1.00 | 0 | 9270 | 1 | SHARP, | | Fatal stroke | 0.87 [0.62 1.20] | p=1.00 | 0 | 9270 | 1 | SHARP, | | Cancer | 0.99 [0.86 1.14] | p=1.00 | 0 | 9270 | 1 | SHARP, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patients: 1 trials - IMPROVE-IT
| ezetimibe vs placebo (on top statins) | cardiovascular events by 6% (fully demonstrated) suggested Coronary event by 13% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.94 [0.89 0.99] | p=0.04 | 0 | 18144 | 1 | IMPROVE-IT, | | Cardiovascular death | 1.00 [0.89 1.13] | p=1.00 | 0 | 18144 | 1 | IMPROVE-IT, | | stroke (fatal and non fatal) | 0.86 [0.73 1.01] | p=1.00 | 0 | 18144 | 1 | IMPROVE-IT, | | Coronary event | 0.87 [0.80 0.95] | p=0.04 | 0 | 18144 | 1 | IMPROVE-IT, | | Coronary death | 0.96 [0.84 1.09] | p=1.00 | 0 | 18144 | 1 | IMPROVE-IT, | | End stage renal disease | no data | | All cause death | 0.99 [0.91 1.07] | p=1.00 | 0 | 18144 | 1 | IMPROVE-IT, | | Fatal stroke | no data | | Cancer | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Diabetic patients : 1 trials - SANDS
| aggressive treatment vs standard teatment | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Venous thromboembolism | no data | | cardiovascular events | 1.35 [0.53 3.41] | p=1.00 | 0 | 499 | 1 | SANDS, | | Cardiovascular death | no data | | stroke (fatal and non fatal) | no data | | Coronary event | no data | | Coronary death and non fatal MI | no data | | Coronary death | no data | | cardiac death | no data | | MACE | no data | | Non fatal MI | no data | | All cause death | no data | | non cardiovascular death | 0.49 [0.09 2.70] | p=1.00 | 0 | 499 | 1 | SANDS, | | Fatal stroke | no data | | Haemmorhagic stroke | no data | | new-onset diabetes | no data | | Death from cancer | no data | | Rhabdomyolysis | no data | | Myopathy | no data | | Cancer | no data | | Adverse events | 1.32 [0.88 1.98] | p=1.00 | 0 | 499 | 1 | SANDS, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
High risk patients with or without LDL cholesterol elevation: 1 trials - ARBITER-HALTS 6
| ezetimibe vs niacin | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | stroke (fatal and non fatal) | no data | | Coronary event | no data | | Coronary death | no data | | End stage renal disease | no data | | All cause death | no data | | Fatal stroke | no data | | Cancer | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patient with related disease: 1 trials - Enhance
| ezetimibe vs placebo (on top statins) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | stroke (fatal and non fatal) | no data | | Coronary event | no data | | Coronary death | no data | | End stage renal disease | no data | | All cause death | no data | | Fatal stroke | no data | | Cancer | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients with prior MI or with CHD: 1 trials - IMPROVE-IT
| ezetimibe vs placebo (on top statins) | cardiovascular events by 6% (fully demonstrated) suggested Coronary event by 13% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.94 [0.89 0.99] | p=0.04 | 0 | 18144 | 1 | IMPROVE-IT, | | Cardiovascular death | 1.00 [0.89 1.13] | p=1.00 | 0 | 18144 | 1 | IMPROVE-IT, | | stroke (fatal and non fatal) | 0.86 [0.73 1.01] | p=1.00 | 0 | 18144 | 1 | IMPROVE-IT, | | Coronary event | 0.87 [0.80 0.95] | p=0.04 | 0 | 18144 | 1 | IMPROVE-IT, | | Coronary death | 0.96 [0.84 1.09] | p=1.00 | 0 | 18144 | 1 | IMPROVE-IT, | | End stage renal disease | no data | | All cause death | 0.99 [0.91 1.07] | p=1.00 | 0 | 18144 | 1 | IMPROVE-IT, | | Fatal stroke | no data | | Cancer | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients with renal insufficiency (on hemodialysis or transplant): 1 trials - SHARP
| ezetimibe+simvastatin vs placebo | No demonstrated result suggested cardiovascular events by 13% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.87 [0.78 0.97] | p=0.04 | 0 | 9270 | 1 | SHARP, | | Cardiovascular death | no data | | stroke (fatal and non fatal) | no data | | Coronary event | 0.92 [0.76 1.11] | p=1.00 | 0 | 9270 | 1 | SHARP, | | Coronary death | no data | | End stage renal disease | 0.97 [0.88 1.07] | p=1.00 | 0 | 9270 | 1 | SHARP, | | All cause death | 1.02 [0.93 1.12] | p=1.00 | 0 | 9270 | 1 | SHARP, | | Fatal stroke | 0.87 [0.62 1.20] | p=1.00 | 0 | 9270 | 1 | SHARP, | | Cancer | 0.99 [0.86 1.14] | p=1.00 | 0 | 9270 | 1 | SHARP, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Diabetic patients with or withour hypercholesterolemia: 1 trials - SANDS
| aggressive treatment vs standard teatment | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Venous thromboembolism | no data | | cardiovascular events | 1.35 [0.53 3.41] | p=1.00 | 0 | 499 | 1 | SANDS, | | Cardiovascular death | no data | | stroke (fatal and non fatal) | no data | | Coronary event | no data | | Coronary death and non fatal MI | no data | | Coronary death | no data | | cardiac death | no data | | MACE | no data | | Non fatal MI | no data | | All cause death | no data | | non cardiovascular death | 0.49 [0.09 2.70] | p=1.00 | 0 | 499 | 1 | SANDS, | | Fatal stroke | no data | | Haemmorhagic stroke | no data | | new-onset diabetes | no data | | Death from cancer | no data | | Rhabdomyolysis | no data | | Myopathy | no data | | Cancer | no data | | Adverse events | 1.32 [0.88 1.98] | p=1.00 | 0 | 499 | 1 | SANDS, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patients: 1 trials - Enhance
| ezetimibe vs placebo (on top statins) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | stroke (fatal and non fatal) | no data | | Coronary event | no data | | Coronary death | no data | | End stage renal disease | no data | | All cause death | no data | | Fatal stroke | no data | | Cancer | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patients: 1 trials - IMPROVE-IT
| ezetimibe vs placebo (on top statins) | cardiovascular events by 6% (fully demonstrated) suggested Coronary event by 13% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.94 [0.89 0.99] | p=0.04 | 0 | 18144 | 1 | IMPROVE-IT, | | Cardiovascular death | 1.00 [0.89 1.13] | p=1.00 | 0 | 18144 | 1 | IMPROVE-IT, | | stroke (fatal and non fatal) | 0.86 [0.73 1.01] | p=1.00 | 0 | 18144 | 1 | IMPROVE-IT, | | Coronary event | 0.87 [0.80 0.95] | p=0.04 | 0 | 18144 | 1 | IMPROVE-IT, | | Coronary death | 0.96 [0.84 1.09] | p=1.00 | 0 | 18144 | 1 | IMPROVE-IT, | | End stage renal disease | no data | | All cause death | 0.99 [0.91 1.07] | p=1.00 | 0 | 18144 | 1 | IMPROVE-IT, | | Fatal stroke | no data | | Cancer | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
